108 related articles for article (PubMed ID: 8683256)
1. Safety profile of single-dose dexamethasone premedication for paclitaxel.
Parikh B; Khanolkar S; Advani SH; Dhabhar B; Chandra M
J Clin Oncol; 1996 Jul; 14(7):2189-90. PubMed ID: 8683256
[No Abstract] [Full Text] [Related]
2. Paclitaxel premedication regimens.
Boehm DK; Maksymiuk AW
J Natl Cancer Inst; 1996 Apr; 88(7):463-5. PubMed ID: 8618242
[No Abstract] [Full Text] [Related]
3. Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel.
Gennari A; Salvadori B; Tognoni A; Conte PF
Ann Oncol; 1996 Nov; 7(9):978-9. PubMed ID: 9006754
[No Abstract] [Full Text] [Related]
4. Single-dose dexamethasone paclitaxel premedication.
Micha JP; Rettenmaier MA; Dillman R; Fraser P; Birk C; Brown JV
Gynecol Oncol; 1998 May; 69(2):122-4. PubMed ID: 9600818
[TBL] [Abstract][Full Text] [Related]
5. Prophylaxis for paclitaxel hypersensitivity reactions.
Kintzel PE
Ann Pharmacother; 2001 Sep; 35(9):1114-7. PubMed ID: 11573863
[TBL] [Abstract][Full Text] [Related]
6. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
Bookman MA; Kloth DD; Kover PE; Smolinski S; Ozols RF
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-13-S19-15. PubMed ID: 9427258
[TBL] [Abstract][Full Text] [Related]
7. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens.
Kloover JS; den Bakker MA; Gelderblom H; van Meerbeeck JP
Br J Cancer; 2004 Jan; 90(2):304-5. PubMed ID: 14974481
[TBL] [Abstract][Full Text] [Related]
8. Intravenous versus oral dexamethasone premedication in preventing Paclitaxel infusion hypersensitivity reactions in gynecological malignancies.
O'Cathail SM; Shaboodien R; Mahmoud S; Carty K; O'Sullivan P; Blagden S; Gabra H; Whear S; Kwon JS; Agarwal R
Int J Gynecol Cancer; 2013 Sep; 23(7):1318-25. PubMed ID: 23907557
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of the effects of oral and intravenous dexamethasone premedication in the prevention of paclitaxel-induced allergic reactions.
Chen FC; Wang LH; Zheng XY; Zhang XM; Zhang J; Li LJ
Oncotarget; 2017 Mar; 8(12):19236-19243. PubMed ID: 27911278
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.
Berger MJ; Dunlea LJ; Rettig AE; Lustberg MB; Phillips GS; Shapiro CL
Support Care Cancer; 2012 Sep; 20(9):1991-7. PubMed ID: 22089428
[TBL] [Abstract][Full Text] [Related]
11. [A patient with paclitaxel hypersensitivity treated with nab-paclitaxel].
Ouchi A; Ouchi A; Asano M; Aono K; Watanabe T; Kato T
Gan To Kagaku Ryoho; 2014 Jul; 41(7):889-91. PubMed ID: 25131878
[TBL] [Abstract][Full Text] [Related]
12. Oral premedication for the prevention of hypersensitivity reactions to paclitaxel.
Zidan J; Hussein O; Abzah A; Tamam S; Farraj Z; Friedman E
Med Oncol; 2008; 25(3):274-8. PubMed ID: 18363113
[TBL] [Abstract][Full Text] [Related]
13. Tapering and discontinuation of glucocorticoid prophylaxis during prolonged weekly to biweekly paclitaxel administration.
Braverman AS; Rao S; Salvatti ME; Adamson B; McManus M; Pierre S
Chemotherapy; 2005 May; 51(2-3):116-9. PubMed ID: 15886470
[TBL] [Abstract][Full Text] [Related]
14. A feasibility study of 1-h paclitaxel infusion in patients with solid tumors.
Tsavaris N; Polyzos A; Kosmas C; Giannikos L; Gogas J
Cancer Chemother Pharmacol; 1997; 40(4):353-7. PubMed ID: 9225955
[TBL] [Abstract][Full Text] [Related]
15. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.
Hudis CA; Seidman AD; Crown JP; Balmaceda C; Freilich R; Gilewski TA; Hakes TB; Currie V; Lebwohl DE; Baselga J; Raptis G; Gollub M; Robles M; Bruno R; Norton L
J Clin Oncol; 1996 Jan; 14(1):58-65. PubMed ID: 8558221
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors.
Sui M; Chen F; Chen Z; Fan W
Int J Cancer; 2006 Aug; 119(3):712-7. PubMed ID: 16496381
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic effect of pemirolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancer.
Yahata H; Saito M; Sendo T; Itoh Y; Uchida M; Hirakawa T; Nakano H; Oishi R
Int J Cancer; 2006 May; 118(10):2636-8. PubMed ID: 16353140
[TBL] [Abstract][Full Text] [Related]
18. Hypersensitivity reaction to paclitaxel: nursing interventions.
Myers JS
Clin J Oncol Nurs; 2000; 4(4):161-3. PubMed ID: 11261096
[TBL] [Abstract][Full Text] [Related]
19. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.
Gradishar WJ; Tjulandin S; Davidson N; Shaw H; Desai N; Bhar P; Hawkins M; O'Shaughnessy J
J Clin Oncol; 2005 Nov; 23(31):7794-803. PubMed ID: 16172456
[TBL] [Abstract][Full Text] [Related]
20. A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors.
Zhang Q; Huang XE; Gao LL
Biomed Pharmacother; 2009 Sep; 63(8):603-7. PubMed ID: 19019625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
